Piramal Pharma Ltd

Piramal Pharma experienced a notable rebound on February 17, 2025, after seven days of decline, outperforming its sector. The stock reached an intraday high, although it remains below key moving averages. In contrast to the broader market, Piramal Pharma has faced significant volatility over the past month.

Piramal Pharma's stock has declined for seven consecutive days, resulting in a total drop of 16.19%. The stock underperformed compared to the broader pharmaceuticals sector and is trading below key moving averages, indicating a bearish trend. Over the past month, it has decreased by 17.73%.

Piramal Pharma has faced a significant decline in stock performance, losing 3.43% today and underperforming its sector. The stock has dropped 14.58% over the past five days and is trading below its moving averages, indicating ongoing challenges in the current market environment compared to broader indices.

Piramal Pharma has faced a significant decline in stock performance, marking its fourth consecutive day of losses and a cumulative drop over this period. The company's performance has lagged behind its sector, with mixed trends in moving averages and a notable decline over the past month compared to the broader market.

Piramal Pharma has demonstrated significant trading activity, outperforming its sector. The stock is currently above its short-term moving averages but below its medium-term averages. Over various time frames, it has shown mixed performance, with a recent one-day gain contrasting with a decline over the past month.

Piramal Pharma has demonstrated significant trading activity, outperforming its sector. The stock is currently above its short-term moving averages but below its medium-term averages. Over various time frames, it has shown mixed performance, with a recent one-day gain contrasting with a decline over the past month.

Piramal Pharma has demonstrated significant activity, outperforming its sector in the Pharmaceuticals & Drugs industry. The stock's current price is above several moving averages, indicating a positive short-term trend, while facing challenges in the medium term. Recent performance reflects volatility within the pharmaceutical sector amid changing market conditions.

Piramal Pharma has faced a decline of 3.48% on January 30, 2025, underperforming its sector. The stock is above its 5-day and 200-day moving averages but below the 20-day, 50-day, and 100-day averages. Over the past month, it has decreased by 12.85%, highlighting ongoing market challenges.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.

Piramal Pharma experienced significant trading activity on January 29, 2025, recovering from a prior decline. After an initial drop, the stock reached an intraday high, indicating a potential trend reversal. Its performance over the past month contrasts with broader market trends, reflecting volatility in the pharmaceuticals sector.